HK Stock Market Move | GIANT BIOGENE (02367) fell more than 6% in the afternoon. The promotion of new medical and beauty products from approval to market still requires a certain amount of preparation time.

GIANT BIOGENE (02367) fell more than 6% in the afternoon, dropping 4.51% to HK$39.8 as of press time, with a turnover of HK$5.13 billion. On the news front, GIANT BIOGENE previously announced that its three types of medical devices "recombinant Type I 1 Collagen freeze-dried fibers" have been approved. This product is China's first recombinant Type I natural sequence collagen facial injection product, which was formally approved through the joint review of the medical device and drug administration. Huatai stated that considering the preparation time needed for the new medical beauty product to be approved and promoted, they maintain the company's net profit forecast for 2025-2027. Zhongtai International published a report pointing out that Kemei's online sales performance was relatively weak in the first phase of the Double Eleven event. The Bank estimated that Kemei's online income in the second half of the year may decline by 10% year-on-year, dragging down Kemei's full-year online income growth rate to around 5%. However, Colgate's full-year online income is expected to achieve a high growth of about 40%. Offline business is expected to maintain steady growth. The Bank expects the company's revenue growth forecast for 2025 to slow to 12%.